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ABSTRACT: Dried blood spot (DBS) sampling is recognized as a valuable alternative sampling strategy both in research and in
clinical routine. Although many advantages are associated with DBS sampling, its more widespread use is hampered by several
issues, of which the hematocrit eﬀect on DBS-based quantitation remains undoubtedly the most widely discussed one. Previously,
we developed a method to derive the approximate hematocrit from a nonvolumetrically applied DBS based on its potassium
content. Although this method yielded good results and was straightforward to perform, it was also destructive and required
sample preparation. Therefore, we now developed a nondestructive method which allows to predict the hematocrit of a DBS
based on its hemoglobin content, measured via noncontact diﬀuse reﬂectance spectroscopy. The developed method was
thoroughly validated. A linear calibration curve was established after log/log transformation. The bias, intraday and interday
imprecision of quality controls at three hematocrit levels and at the lower and upper limit of quantitation (0.20 and 0.67,
respectively) were less than 11%. In addition, the inﬂuence of storage and the volume spotted was evaluated, as well as DBS
homogeneity. Application of the method to venous DBSs prepared from whole blood patient samples (n = 233) revealed a good
correlation between the actual and the predicted hematocrit. Limits of agreement obtained after Bland and Altman analysis were
−0.076 and +0.018. Incurred sample reanalysis demonstrated good method reproducibility. In conclusion, mere scanning of a
DBS suﬃces to derive its approximate hematocrit, one of the most important variables in DBS analysis.
Over the last decades, dried blood spot (DBS) samplinghas been increasingly recognized as a valuable alternative
sampling strategy in ample domains,1 such as newborn
screening,2 therapeutic drug monitoring,3,4 and toxicology,5,6
because of the various advantages that are associated with it.
Indeed, DBS sampling is minimally invasive, requires only very
small volumes of blood and allows for home-based patient self-
sampling.7 Nonetheless, DBSs still struggle to be implemented
on a routine basis in quantitative bioanalysis. Among the prime
causes for this is the so-called hematocrit (Hct) eﬀect, which
entails that the Hct of the blood used to prepare a DBS may
inﬂuence the obtained result.8 Indeed, with varying Hct, and
hence, varying blood viscosity, blood will spread diﬀerently
throughout the ﬁlter paper, leading to a diﬀerent volume of
blood being analyzed when a ﬁxed-size DBS punch is sampled.
The latter is often preferred over whole DBS analysis after
volumetric DBS application to enable simplicity of sample
collection, especially when samples need to be collected by the
patient himself in a home setting. In addition, the Hct may also
inﬂuence analyte recovery, matrix eﬀect and DBS homoge-
neity.9 Driven by the impact of this Hct issue on the future of
quantitative DBS analysis, ample solutions have already been
proposed. These include the analysis of complete ﬁxed-volume
DBSs10−14 or other dried blood samples,15,16 Hct prediction
and subsequent Hct eﬀect correction,17,18 the use of new
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substrates on which the spreading of the blood is Hct-
independent,19 and the use of in situ-generated dried plasma
spots (DPSs).20,21 However, all of these solutions have certain
limitations or drawbacks, as has been elaborately discussed
elsewhere.8,22−24
Previously, we developed a method which uses the potassium
(K+) content of a DBS extract to predict its Hct.17 Although
this method yielded excellent results when applied to real
patient samples and was able to adequately correct for the Hct
eﬀect using caﬀeine and paraxanthine as model compounds,18 it
suﬀered from some practical drawbacks. Indeed, part of the
DBS needed to be sacriﬁced for the K+ analysis, which also
required an additional sample preparation. Therefore, we set
out to develop a noncontact method to predict the Hct of
DBSs, since such a method would preserve the entire DBS
sample and exclude the need for sample preparation, which in
turn could facilitate integration in existing DBS analyzers. More
particularly, it was our goal to develop a noncontact method
that allows to predict the Hct of a DBS, based on its total Hb
content.
Since previous experiments performed at our laboratory
showed that Hb, upon aging of DBSs, is converted from
oxyhemoglobin (OxyHb) to methemoglobin (MetHb),8 which
is also accompanied by spectral changes (cfr. the change in
color of a DBS upon aging), both Hb forms need to be taken
into account to allow spectrometry-based Hb quantitation.
However, even when doing so, the Hb sum proved to be
unstable in function of time. Interestingly, Bremmer et al.
demonstrated that in aging blood stains Hb is originally present
as OxyHb, which is then oxidized to MetHb and further
denatured to hemichrome (HC). Therefore, we hypothesized
that if a similar process would occur in DBSs and no other
major Hb derivatives or metabolites were formed upon aging,
the sum of OxyHb, MetHb and HC (i.e., “total Hb”) would
remain constant and could be used as a marker of Hct. As a
basis for the development of the noncontact method we used
the work of Bremmer et al. and Edelman et al., who used
noncontact diﬀuse reﬂectance spectroscopy to determine the
relative abundance of Oxy-Hb, MetHb and HC in dried blood
stains at crime scenes for age estimation purposes.25,26 For the
Hct prediction of DBSs, however, these three Hb derivatives
had to be determined quantitatively, rather than qualitatively,
which required alteration and optimization of the method.
Total Hb has been previously determined colorimetrically in
DBS extracts either “as is”8 or after transformation of Hb into
its cyano-methemoglobin derivative via extraction of the DBS
in Drabkin’s reagent.27−29 However, in each case the age of the
DBSs inﬂuenced the obtained results. Others have used the
total area under the curve of all Hb variants determined via
HPLC-UV during hemoglobinopathy screening as a measure of
total Hb and Hct, albeit only semiquantitative results could be
achieved.30 Furthermore, LC-MS/MS has been successfully
employed to determine total Hb by measuring a proteospeciﬁc
peptide after tryptic digestion of a DBS extract.31 Unfortu-
nately, this method is not suitable for Hct prediction of DBSs,
since in many cases the Hct prediction would be more
complicated than the analysis of the actual target analyte.
Additionally, Miller et al. tried to utilize the Hb bands at 540
and/or 570 nm, measured with noncontact diﬀuse reﬂectance
spectroscopy, as a measure of a DBS’ Hct.32 Although these
authors did not ﬁnd a correlation between the Hct and the
reﬂectance at these Hb-speciﬁc wavelengths, they did ﬁnd a
correlation with the background scattering measured at 980
nm. The same optical technique has also been employed by
Cecchi et al. to measure total Hb after transformation of Hb
into its isothiocyano-methemoglobin derivative.33 To that end,
derivatizing reagents were preimpregnated in a nylon-based
ﬁlter paper used to collect DBSs. Another noncontact method
to determine total Hb was published by Yang et al., which
encompassed mixing Drabkin’s reagent and blood before
deposition of the sample onto the ﬁlter paper and using the
color intensity determined on a digitized image of the DBS as a
measure of total Hb.34 However, such an approach would not
be feasible in the context of home-sampling.
In this Article, we describe a method that allows to predict
the Hct of a regular, nonvolumetrically applied DBS, based on
its Hb content using noncontact diﬀuse reﬂectance spectros-
copy. In contrast to other published DBS-based total Hb
analyses, this method is quantitative, nondestructive, applicable
on both fresh and old DBS, does not require any sample
preparation nor ﬁlter paper pretreatment, and allows to predict
the Hct of a DBS. This method was thoroughly validated,
yielding acceptable accuracy and precision, and was applied to a
diverse patient population, yielding satisfactory results.
■ EXPERIMENTAL SECTION
Preparation of DBS Samples. Venous blood was collected
from consenting healthy volunteers in blood collection tubes
with lithium heparin (Li-heparin) as anticoagulant (Venosafe,
VF-109SHL, Terumo, Leuven, Belgium). DBSs were prepared
at the day of blood collection by depositing 25 μL of blood
onto Whatman 903 ﬁlter paper (GE Healthcare, Dassel,
Germany), unless mentioned otherwise. Blood spots were
always allowed to dry at ambient conditions for at least 2 h. The
obtained DBSs were either analyzed immediately after drying or
were stored in zip-locked plastic bags in the presence of a
desiccant until analysis (Minipax, Sigma-Aldrich, Diegem,
Belgium). Blood samples with diﬀerent Hct were prepared by
centrifuging an aliquot of venous whole blood in 2 mL safe-lock
tubes in an Eppendorf 5417R centrifuge (Eppendorf, Hamburg,
Germany) for 5 min at 1000 g, followed by the removal or
addition of a suitable amount of plasma. For evaluating the
inﬂuence of the presence of diﬀerent anticoagulants on the
measured reﬂectance, venous blood from a healthy volunteer
was collected in blood collection tubes with either Li-heparin,
sodium ﬂuoride (NaF)/oxalate (Venosafe, VF-052SFX, Ter-
umo), ethylenediaminetetraacetic acid dipotassium (K2EDTA)
or citrate as anticoagulant and in a blood collection tube
without any anticoagulant (all from BD Vacutainer, Becket
Dickinson B.V., Breda, The Netherlands). The DBSs without
anticoagulant were prepared within 1 min after blood
collection. Patient samples were prepared similarly to the
ones from healthy volunteers and were collected in Li-heparin
(Venosafe, VF-106SAHL and VF-054SAHL, Terumo) or
K2EDTA-containing blood collection tubes (Venosafe, VF-
054SDK, Terumo).
Analysis. Hct measurements on venous whole blood were
performed using a Sysmex XE-5000 hematology analyzer
(Sysmex Corporation, Kobe, Japan) and are expressed as L/L
throughout the manuscript. All Hct measurements during
method development and validation were performed at the
Laboratory of General Clinical Chemistry (LAKC) at the
Academic Medical Center (AMC), Amsterdam, while the Hct
measurements of the patient samples were performed at the
Laboratory of Clinical Biology at Ghent University Hospital.
The analyzer at Ghent University Hospital was also used for the
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mean corpuscular hemoglobin concentration (MCHC) analysis
of the patient samples. Additionally, the hemolytic, lipemic and
icteric index of the patient samples were determined using a
Cobas 8000 analyzer at Ghent University Hospital.
Noncontact diﬀuse reﬂectance spectroscopy was employed
to determine the total Hb content and Hct (L/L) of the DBSs.
The setup that was used to acquire the spectral data (depicted
in Figures 1 and S-1) comprised a 10W tungsten-halogen light
source (AvaLight-HAL, Avantes, Appeldoorn, The Nether-
lands), a spectrometer (USB4000, Ocean Optics, Duiven, The
Netherlands) and a noncontact ﬁber-probe (QR400-7-UV/BX,
Ocean Optics, Duiven, The Netherlands). The ﬁber-probe
consisted of a collection ﬁber encircled by six delivery ﬁbers. All
ﬁbers had a core diameter of 400 μm. The probe tip was placed
1.3 cm above the sample and set at a slight angle to avoid
specular reﬂection. Moreover, a neutral density ﬁlter with an
optical density of 0.4 was inserted between the light source and
the delivery ﬁbers to prevent detector saturation. In this setup,
the light source output was guided toward the sample surface
via the six delivery ﬁbers, illuminating a 5.9 mm-diameter spot,
which corresponds approximately to a traditional 6 mm-punch.
Light reﬂected by the DBS was guided to the spectrometer by
the central collection ﬁber. The spectrometer recorded the
wavelength dependence of the reﬂected light intensity
(reﬂection spectrum) between 354 and 1042 nm using the
SpectraSuite software (Ocean Optics, Duiven, The Nether-
lands). In addition to the recording of a reﬂection spectrum of
each DBS, also the reﬂection spectrum of a white reference was
recorded. The integration time was set at 20 ms and 20 spectra
were averaged for one measurement. All recorded spectra were
corrected for the electrical dark noise of the detector.
Spectral Data Analysis. All data analysis was carried out
using custom-made scripts written in MATLAB R2012a (The
Mathworks Inc., Natick, MA, USA). Wavelength-dependent
reﬂectance values R(λ) were obtained from the measured
spectra using the following formula (eq 1):
λ λ
λ
=R I
I
( )
( )
( )white (1)
Here, λ corresponds to the wavelength of the light. Further,
I(λ) refers to the light intensity reﬂected by a DBS, while
Iwhite(λ) denotes the light intensity reﬂected by the white
reference. Applying eq 1 to the data served as a normalization
step, normalizing the light intensity reﬂected by the DBSs to
the light intensity reﬂected by the nonlight-absorbing white
reﬂectance standard. R(λ) was then compared to a one-
dimensional light-transport model for multilayered samples.35
This light-transport model describes the wavelength-dependent
reﬂectance of a DBS as a combination of light absorption and
light scattering and takes into account the optical properties of
both the blood and the blank ﬁlter paper. In this model the
inﬂuence of the blank ﬁlter paper is described by its measured
wavelength-dependent reﬂectance and the wavelength-depend-
ent optical properties of the blood are described by an
absorption coeﬃcient and a scattering coeﬃcient. Light
absorption in the DBSs is mainly attributed to three
hemoglobin derivatives which are assumed to be present,
namely, OxyHb, MetHb, and HC. The overall absorption
coeﬃcient of the blood is therefore modeled as a linear
combination of the individual absorption coeﬃcients of the
three Hb derivatives. Reference curves for these three
absorption coeﬃcients were taken from Bremmer et al.25 For
a given DBS, the present amounts of the Hb derivatives were
calculated by ﬁtting the output of the light-transport model to
the measured R(λ) in the spectral range of 500−700 nm,
employing a nonlinear least-squares ﬁtting algorithm. The
range of 500−700 nm was used in the ﬁtting procedure, since
during method optimization this proved to yield the best ﬁt
between the measured spectra and the reference spectra. The
least-squares ﬁtting algorithm assigned a value with arbitrary
units to each of the Hb derivatives and the sum of those values
was then used as a measure of total Hb and Hct. To further
clarify the spectral data analysis process, a ﬂowchart was
included in Figure S-2.
Validation. To choose a calibration model, we set up six 7-
point calibration curves in DBSs, prepared from blood with a
Hct of 0.20, 0.27, 0.35, 0.41, 0.49, 0.57, and 0.66. All calibrators
were generated from the blood of a single donor. Unweighted
and weighted (1/x, 1/x2, 1/y, 1/y2) linear regression models, a
second order regression model, a power regression model, as
well as a linear regression model after transformation of the
data (logaritmic or square root) were compared. The choice of
the calibration model was based upon the sum of the absolute
percent relative errors (% RE) and the distribution of the RE in
function of Hct.36 Linearity was evaluated using an F-test,
acceptance of a linear model was based upon the backcalculated
values of all calibrators. A Levene’s test for equality of variances
was performed to assess homoscedasticity.
Accuracy (% bias) and precision (% RSD, relative standard
deviation) were determined based on six 7-point calibration
curves in DBSs, prepared from blood with an approximate Hct
of 0.20, 0.27, 0.35, 0.42, 0.50, 0.57, and 0.65. On each of three
diﬀerent days two calibration curves were set up. Along with
every calibration curve, three DBS quality controls (QCs) with
an approximate Hct of 0.20, 0.42, and 0.65 were prepared from
blood of the same donor. Furthermore, additional QCs were
prepared from ﬁve other blood sources. In addition, six 7-point
calibration curves were also prepared from the blood of a
second donor to exclude that the obtained results would be
donor-dependent. An overview of all calibrators and QCs is
given in Table S-1. As it is not possible to prepare QCs with
exactly the same Hct for each measurement series, these slight
diﬀerences in true Hct had to be taken into account for the
determination of precision. This was done by normalizing the
calculated Hct values to the average true Hct value of a QC
(Table S-2A and S2-B).
Hct predictions based on measurements at the center of the
DBS were compared with those obtained from measurements
at a more peripheral location, avoiding the very edge of the
sample (n = 6). This experiment was performed on 50 μL
DBSs to allow suﬃcient diﬀerence in location between a central
Figure 1. Schematic representation of the used setup.
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and peripheral measurement. The impact of the blood volume
spotted was evaluated in DBSs prepared by applying 15, 20, 25,
or 50 μL of blood on ﬁlter paper (n = 6). Both the impact of
the measuring location and of the applied blood volume were
evaluated at three Hct levels (approximately 0.20, 0.42, and
0.65).
The eﬀect of storage of the DBSs on the Hct prediction was
evaluated by comparing the result from freshly prepared DBSs
(dried for 2 h; three Hct levels, six replicates) with results
obtained after storage at room temperature for 1 day, 5 days, 1
week, 2 months, and 5 months. In addition, the inﬂuence of
storage at 60 °C for 1, 2 or 3 days on the predicted Hct was
evaluated as well. Results were expressed as the average (n = 6)
± standard deviation (SD). Thanks to the nondestructive
nature of the DBS analysis, the fresh spots could be reanalyzed
at later time points. At every time point a fresh calibration curve
(dried for 2 h) was prepared.
Application. The developed method was applied on real-
life clinical samples displaying a wide range of Hct values
(0.205−0.504). The samples had already undergone or were
destined for routine clinical chemistry and/or hematology
analysis and were collected in either Li-heparin tubes or in
K2EDTA tubes. Permission to use these samples was obtained
from the Ethics Committee of Ghent University Hospital
(project number 2015/0931). A ﬁrst set of samples
encompassed 57 Li-heparin whole blood samples that were
used to prepare DBSs upon arrival at the clinical laboratory by
pipetting 25 μL of Li-heparin anticoagulated blood onto ﬁlter
paper. We also prepared DBSs of the corresponding K2EDTA
whole blood samples of these patients. A second set of samples
encompassed 250 K2EDTA left-over samples from which we
prepared DBSs on the same day of blood collection. Samples
for which the routinely determined Hct or MCHC value were
not available were excluded from further data analysis, as will be
discussed in more detail below. This resulted in a ﬁnal data set
of 55 Li-heparin-containing samples with corresponding
K2EDTA samples and 233 “K2EDTA-only” samples. The
DBS were between 5 and 7 days old at the time of analysis.
Incurred sample reanalysis (ISR)with 3 days between the
reanalysis and the original analysiswas performed on the
second set of patient DBSs (n = 233). At least two-thirds of the
repeated measurements should meet the acceptance criterion,
that is, lie within the limits of ±20% of the mean of the original
and the corresponding reanalysis result.37
Data Analysis. Statistical analysis of the data was done
using Medcalc Statistical Software, version 14.12.0 (MedCalc
Software bvba, Ostend, Belgium, http://www.medcalc.org,
2014), SPSS statistics for Windows version 22.0 (IBM Corp,
Armonk, NY, USA, 2013) and Microsoft Excel 2010. For the
determination of intra- and interday imprecision, a model II
ANOVA was used to allow analysis of the components of
variation. Using this ANOVA approach, the value of the
interday imprecision was equated to the intraday imprecision,
whenever the latter would exceed the former. A paired t test (α
= 0.05; 95% CI, conﬁdence interval) was carried out to evaluate
the eﬀect of the measurement location on the predicted Hct.
To evaluate the inﬂuence of diﬀerent volumes of blood spotted,
a one-way ANOVA (α = 0.05) with Bonferroni posthoc test
was employed. Medcalc was used to perform a Levene’s test for
the evaluation of homoscedasticity. Furthermore, the same
software was employed to calculate Pearson correlation
coeﬃcients, to generate Mountain plots and to perform Passing
and Bablok regression analysis on the patient data. The
corresponding Bland and Altman plots were generated in Excel
2010. Furthermore, a paired t test was employed to evaluate
whether a statistically signiﬁcant diﬀerence existed between the
predicted Hct determined on Li-heparin-containing DBSs and
the predicted Hct determined on K2EDTA-containing DBSs.
The presence of outliers was always evaluated using a Grubbs
test.
■ RESULTS AND DISCUSSION
Method Development. Optimization of Setup. To obtain
reproducible reﬂectance spectra, it was of utmost importance to
keep the distance between the probe and the sample constant.
To achieve this, the setup needed to be ﬁxed and the ﬁlter
paper (in sheets, spotted with multiple DBSs) needed to be
kept ﬂat. To that end, a plate was positioned on top of the ﬁlter
paper and pressed down with weights. This plate had a 1 cm
hole in the center (i.e., slightly larger than the DBS that needed
to be analyzed) through which the measurement could be
performed. Importantly, when using DBS cards instead of
sheets of ﬁlter paper, the “waviness” of the substrate after DBS
application and drying is much less of a problem, since the
former are much more rigid in nature. Evidently, although the
method could potentially be applied on either DBS cards or
sheets of ﬁlter paper, it is important to prepare calibrators and
patient samples on the same substrate and to record the
respective spectra with exactly the same setup and hence, with
the same ﬁxed distance between DBS and probe.
To optimize the distance between the probe and the sample,
three diﬀerent distances (i.e., 0.7, 1.3, and 1.7 cm) were
compared, yielding illuminated areas of respectively approx-
imately 3, 6, and 8 mm. The distance of 0.7 cm resulted in a
larger variability in the obtained spectra compared to the two
larger distances (data not shown), likely because of some
inhomogeneity in the DBSs, which we could also observe via
light microscopy (Figure S-3). Since increasing the distance
from 1.3 to 1.7 cm did not lead to a further improvement (i.e., a
further reduction in variability), the distance of 1.3 cm was
selected for the rest of the experiments. The resulting
illumination diameter of 5.9 mm is acceptable, since DBSs
generated from a ﬁnger prick will typically have a larger
diameter.7,38,39
Additionally, the ﬁlter paper was positioned on a black matt
surface to ensure that light going through the ﬁlter paper was
absorbed by the background and not reﬂected toward the
collection ﬁber. Indeed, with varying Hct, and hence variable
amounts of chromophores in a DBS, variable amounts of light
may penetrate the sample and get reﬂected by, for example, a
white background, which would lead to a variable, Hct-
dependent contribution of the background to the measured
reﬂectance.
Selection of the Used Anticoagulant. A procedure aimed at
measuring Hct in DBSs should be applicable to non-
anticoagulated blood, since this is the type of blood that
eventually will be analyzed (e.g., obtained from a ﬁnger prick in
the context of home-based self-sampling). However, because of
practical reasons, it is impossible to perform a validation or
even to set up calibration curves in nonanticoagulated blood.
We therefore compared at an early stage the reﬂectance spectra
of DBSs prepared from blood without anticoagulant with the
reﬂectance spectra of DBSs from blood that was anticoagulated
with Li-heparin, K2EDTA, citrate, or NaF/oxalate. The
reﬂectance spectra of K2EDTA and Li-heparin-containing
DBSs were nearly identical to the spectra of nonanticoagulated
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DBSs (Figure S-4A and S-4B). The spectra of the citrate-
containing DBSs on the other hand had a similar shape as the
spectra from the nonanticoagulated DBSs but showed a
markedly higher reﬂectance. Furthermore, the spectra of the
NaF/oxalate-containing DBSs showed a slightly deviating
shape. Therefore, only Li-heparin and K2EDTA were deemed
suitable anticoagulants to develop the noncontact Hct
prediction method. At this stage, we wished to preserve the
possibility to also analyze the DBS samples with the existing K+-
based method for Hct prediction. Therefore, we opted for Li-
heparin anticoagulated blood to perform the validation.
Method Validation. A power regression model (and the
derived linear regression model after log/log transformation)
yielded the best calibration model. Furthermore, although data
were originally heteroscedastic (p = 0.005), they became
homoscedastic after log/log transformation (p = 0.429).
Although an F-test performed on the logarithmically trans-
formed data showed that the calibration model was statistically
nonlinear, a linear model could be accepted based upon the
backcalculated values of all calibrators, which never deviated
more than 15% (range = −11.57% to 10.48%). The lower and
upper limit of quantiﬁcation (LLOQ and ULOQ) were
arbitrarily set at the average of the lowest, respectively, the
highest calibrator. For donor 1 the LLOQ and ULOQ
corresponded to 0.20 and 0.67, while for donor 2 this was
0.20 and 0.65, respectively. The accuracy, intra- and interday
precision for LLOQ and ULOQ were determined on the back-
calculated values and always met the predetermined acceptance
criteria (i.e., ≤ 20% bias and imprecision for LLOQ and ≤15%
for ULOQ) (Table 1A). Also for the three QC levels % bias
and % RSD did not exceed 11% (Table 1B). As described
above, this experiment was also carried out using blood of a
second donor, yielding very similar results (see Table S-3). Also
when the QCs of donor 2 were inserted in the calibration curve
of donor 1 (or vice versa) the results always complied with the
acceptance criteria (Tables 1C and S-3). Moreover, QCs
prepared from four additional blood sources (donors 3−6)
were ﬁtted into the calibration curves of donor 1 and donor 2,
again leading to acceptable results (Tables 1C and S-3).
As mentioned above, the reﬂectance spectrum of a DBS
changes drastically upon aging because the relative amounts of
the diﬀerent Hb derivatives change throughout time (Figure 2A
and 2B). It was therefore of utmost importance to evaluate the
inﬂuence of storage time on the predicted Hct. Long-term
stability at room temperature did not seem to pose a problem
for up to at least 5 months, as, with a single exception, the
observed diﬀerences never exceeded 15% at all measured time
points and at every Hct level (Figure 2C). Also short-term
storage (up to 3 days) at elevated temperatures (60 °C) did not
seem to aﬀect the obtained results, as can be seen in Figure 2D.
Although one-way ANOVA showed a statistically signiﬁcant
diﬀerence in predicted Hct between DBSs prepared from 15,
20, 25, and 50 μL of blood at all the Hct levels tested (p <
0.05), posthoc analysis revealed that there was no statistical
diﬀerence for any of the applied volumes when compared to
the 25 μL reference volume. Moreover, these diﬀerences were
suﬃciently small to not pose a problem in practice (i.e., ≤8%
compared to the reference of 25 μL) (Figure 3A). These
diﬀerences are likely the result of a diﬀerent degree of
saturation of the ﬁlter paper, with higher sample volumes
leading to a slightly higher saturation of the ﬁlter paper when
compared to smaller volumes. This way, a smaller volume of
blood will be present in a ﬁxed-size DBS punch when a small
volume of blood is deposited on the ﬁlter paper, whereas a
larger volume of blood will be present in a ﬁxed-size DBS
punch when a larger volume of blood is deposited on the ﬁlter
paper. This is a known phenomenon for DBSs, as we described
before.38,40
Although a marginally statistically signiﬁcant diﬀerence (p =
0.04) could be observed between measurements performed in
the center of DBSs of low Hct (Hct = 0.19) compared to
measurements performed at a more peripheral location of the
same DBSs, this diﬀerence is not of practical relevance (i.e., ≤
4%), as can be clearly seen in Figure 3B. Furthermore, for the
measurements at both mid (Hct = 0.41) and high (Hct = 0.65)
Hct neither a statistically signiﬁcant (p = 0.07 and 0.15,
respectively) nor a practically relevant diﬀerence was observed.
Method Application. The newly developed noncontact
method was applied to patient samples with a wide Hct range
(0.205−0.504). The ﬁrst set of samples included 55 Li-heparin
DBSs and their corresponding K2EDTA DBSs. The true Hct of
the patient samples was routinely determined on K2EDTA
Table 1. Overview of the Data for Accuracy and Precision (n
= 6) for Donor 1a
accuracy
(% bias)
intraday precision
(% RSD)
interday precision
(% RSD)
(A)
LLOQ 2.41 2.90 3.97
ULOQ −4.38 4.66 4.66
(B)
QC LOW 0.896 10.7 10.7
QC MID −2.97 2.10 3.08
QC HIGH −2.50 4.63 4.63
(C)
QC LOW
(donor 2)
−1.81 2.30 5.65
QC MID
(donor 2)
0.630 5.56 6.91
QC HIGH
(donor 2)
0.857 7.38 7.38
QC LOW
(donor 3)
3.42 5.12 6.80
QC MID
(donor 3)
5.48 2.67 3.67
QC HIGH
(donor 3)
2.65 3.89 5.36
QC LOW
(donor 4)
1.62 6.42 6.42
QC MID
(donor 4)
0.629 7.68 8.38
QC HIGH
(donor 4)
−2.11 5.67 5.67
QC LOW
(donor 5)
4.01 7.77 7.77
QC MID
(donor 5)
−2.82 6.52 6.52
QC HIGH
(donor 5)
0.927 3.00 3.00
QC LOW
(donor 6)
5.13 5.45 6.15
QC MID
(donor 6)
4.92 11.8 11.8
QC HIGH
(donor 6)
4.34 10.8 10.8
aSections A and B, respectively, give the data obtained for the LOQs
(LLOQ and ULOQ) and QCs, prepared from blood of the same
donor as the one in which the calibration curves were prepared.
Section C gives the data for QCs prepared from blood of ﬁve other
donors than the one in which the calibration curves were prepared.
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anticoagulated whole blood, while the noncontact method was
employed to predict the Hct of the DBSs. A good correlation (r
= 0.93) was observed between the predicted Hct of the Li-
heparin DBSs and the true Hct. Nonetheless, Passing and
Bablok regression analysis revealed a statistically signiﬁcant
diﬀerence. The 95% CIs of the slope and the intercept were
0.76 to 0.92 and −0.011 to 0.031, respectively, indicating the
presence of a proportional error (1 is not included in the CI of
the slope) but not of a systemic error (0 is included in the CI of
the intercept). When the diﬀerences between the predicted and
the true Hct were plotted versus the true Hct, an average bias of
−0.031 could be observed (with a range of −0.069 to 0.014).
However, importantly, aside from two exceptions which
deviated −21.0% and −21.1%, respectively, all predicted Hct
values were within ±20% of the true Hct (Figure S-5),
indicating that the noncontact method is ﬁt for purpose (i.e., an
approximate prediction of the Hct of a DBS).
Figure 2. (A) The reﬂectance spectra of a DBS recorded after 2 h, 1 day, 1 week, 1 month. and 5 months. The DBS which was analyzed had an
approximate Hct of 0.20. (B) The amounts of OxyHb, MetHb, and HC present in DBSs up to ﬁve months. The DBSs which were analyzed had an
approximate Hct of 0.20. Note the logaritmic scale of the x-axis. (C) The inﬂuence of storage at room temperature for up to ﬁve months on
estimated Hct, at three Hct levels. At each Hct level, the average estimated Hct value at T0 was used as a reference value. (D) The inﬂuence of
storage at elevated temperatures (60 °C) for up to 3 days on estimated Hct, at three Hct levels. At each Hct level, the corresponding DBSs stored
under ambient conditions were used as a reference. The horizontal lines indicate the 15% acceptance levels. For panel B, C and D average values (n =
6) are depicted. In panels C and D, the error bars indicate SD.
Figure 3. (A) Volume eﬀect: Inﬂuence of the volume used to generate DBSs on the estimated Hct, at three Hct levels. Per Hct level the 25 μL DBSs
were taken as the reference. (B) Volcano eﬀect: Inﬂuence of the measurement localization on the estimated Hct, at three Hct levels. Per Hct level the
measurements at a central localization were taken as a reference. Depicted in each graph are the averages (n = 6) ± SD. Results diﬀering signiﬁcantly
(p < 0.05) from the reference have been indicated with an asterisk.
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Next, the predicted Hct determined on the Li-heparin DBSs
was compared with the predicted Hct determined on the
corresponding K2EDTA DBSs. The Pearson correlation
coeﬃcient was 0.95, implying a good correlation between
results obtained from Li-heparin and K2EDTA DBSs. In
addition, no statistically signiﬁcant diﬀerence was found
between both matrices after applying a paired t test (p =
0.19). Therefore, it was concluded that the noncontact method
could be applied on both Li-heparin and K2EDTA DBSs.
In a next step, the method was applied to a second,
independent set of 233 K2EDTA-containing DBSs. Again, a
good correlation (r = 0.95) was observed between the predicted
and true Hct (Figure 4A). Yet, Passing and Bablok regression
analysis demonstrated that a slight systemic error was present
since the 95% CI of the intercept did not contain 0 (−0.056 to
−0.022), whereas no proportional error could be detected as 1
was included in the 95% CI of the slope (0.98 to 1.07).
Furthermore, a Mountain plot (Figure 4C) depicting the
distribution of the diﬀerences between the predicted and true
Hct, showed a symmetrical distribution around a bias of
approximately −0.029. This can also be observed in the Bland
and Altman plot (Figure 4B), showing a mean diﬀerence of
−0.029 (95% CI = −0.032 to −0.026) and limits of agreement
(LoAs) of −0.076 (95% CI = −0.081 to −0.070) and 0.018
(95% CI = 0.012 to 0.023). These LoAs are similar to the ones
that we obtained for our K+-based method for Hct prediction
which has already proven to successfully alleviate Hct bias in
the quantitative DBS-based analysis of caﬀeine and para-
xanhthine.17,18 Hence, these LoAs (i.e., the degree of error)
were considered acceptable for the intended purpose.
Importantly, 95% of the predicted Hct values were within
20% of the corresponding true Hct.
We identiﬁed several factors that may have contributed to
the observed slight negative bias. First, the “true” Hct of the
patient samples was determined on K2EDTA anticoagulated
whole blood, while the “true” Hct of the calibrators was
routinely determined on Li-heparin anticoagulated whole
blood. The latter gives a slightly lower hematocrit than the
former, on average.17 Second, because of logistical reasons, all
Hct measurements on patient whole blood were performed in
Ghent University Hospital, whereas the Hct measurements on
the whole blood used to prepare the calibrators that were used
to analyze the patient samples were performed in the AMC
Amsterdam. Small diﬀerences may have been present between
the results obtained in both laboratories. Furthermore, a clear
inﬂuence of the patient’s MCHC value on the predicted Hct
was observed. The MCHC is a measure of the concentration of
Hb in a given number of packed red blood cells and is
calculated by dividing the Hb content of a sample by the Hct.
We observed that the lower the patients’ MCHC values were,
the more pronounced the underestimation of their Hct values
was on average (Figure S-6). In addition, the inﬂuence of the
hemolytic, lipemic, and icteric indexes on the predicted Hct was
evaluated. However, none of these parameters seemed to have a
noticeable inﬂuence on the obtained results (Figure S-7).
Incurred sample reanalysis performed on the second set of
patient samples (n = 233) revealed good method reproduci-
bility. After the removal of one outlier (54%; conﬁrmed with a
Grubbs test, p < 0.05) all data points were within the
acceptance criterion of ±20% (95% were within ±8%).
■ CONCLUSION
We successfully developed a noncontact method to predict the
Hct of a DBS based on its total Hb content. In contrast to other
published DBS-based total Hb analyses, this method is
quantitative, nondestructive, does not require any sample
preparation nor ﬁlter paper pretreatment, and most impor-
tantly, allows to predict the Hct of both fresh and old DBSs.
This method was thoroughly validated and complied with all
the predeﬁned acceptance criteria generally used for bio-
analytical procedures. Application on patient samples with a
wide Hct range showed the applicability of this method on real
patient samples. Although a slight bias could be observed,
which could be attributed to (a combination of) several factors,
this does not jeopardize the usefulness of the approach. This
noncontact diﬀuse reﬂectance spectroscopy-based method
overcomes the need for sample preparation, which in turn
reduces the analysis time, minimizes the possibility of errors
and, importantly, eliminates the need for sample destruction.
Indeed, no part of the already limited sample volume of DBSs
needs to be sacriﬁced for the additional Hct analysis, since mere
scanning of a DBS suﬃces to derive the approximate Hct of the
sample, one of the most important variables in DBS analysis.
The predicted Hct could either be used to evaluate whether the
Hct of a sample lies within the valid Hct range established
during method validation or to correct the obtained result for
the Hct eﬀect anticipated at that Hct value. In both cases it is
important to know the Hct of a DBS, even if the Hct value
could also be determined on a corresponding liquid venous
whole blood sample, as the venous and capillary Hct may not
be the same.41 In addition, the capillary Hct also shows more
variation during consecutive measurements than the venous
Figure 4. (A) Comparison of predicted and true patient Hct values and corresponding regression line. Also depicted is the line of equality. (B) Bland
and Altman comparison of predicted and true Hct. Depicted are the mean diﬀerence, the upper and lower LoAs (all with their respective 95% CIs)
and the 20% acceptance criteria. (C) Mountain plot depicting the distribution of the diﬀerences between the predicted and the true Hct. In all
graphs, the true Hct refers to the Hct determined on EDTA-anticoagulated whole blood.
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Hct does,42 which may cause a larger variation in capillary
analyte concentrations, as the latter are all subject to a (slightly)
diﬀerent Hct eﬀect. Yet again, knowing the DBS’s Hct may be
beneﬁcial in this context, as correcting the capillary DBS analyte
concentration based on the predicted Hct of that exact DBS
may help to reduce the variability. In addition, the predicted
Hct may also be used to convert a DBS-based analyte
concentration into the corresponding plasma-based concen-
tration. Such a blood−plasma conversion is typically required
to allow comparison of the DBS-based result with existing
plasma-based reference values or therapeutic intervals and is
often Hct-dependent, since the distribution of a compound
between the red blood cell- and plasma fraction is often
inﬂuenced by the amount of red blood cells present (i.e., a
patient’s Hct). Importantly, all the solutions which have
hitherto been suggested to cope with the Hct eﬀect on the
spreading of the blood through the ﬁlter paper still yield a dried
blood sample and therefore a dried blood sample-based result,
necessitating a blood-plasma conversion and hence, a Hct
determination in those cases as well. The only exception to this
is the use of in situ generated DPSs. However, also this
approach has its (Hct-related) issues.23
In future, the newly developed noncontact method will have
to be applied on true capillary samples and it will need to be
evaluated whether the predicted Hct will allow adequate Hct
eﬀect correction. Moreover, since the employed equipment is
simple and compact, automation of this analysis can be easily
envisaged.
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